-
1
-
-
78751549662
-
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia
-
Herishanu Y, Pérez-Galán P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117(2):563-574.
-
(2011)
Blood
, vol.117
, Issue.2
, pp. 563-574
-
-
Herishanu, Y.1
Pérez-Galán, P.2
Liu, D.3
-
2
-
-
84859398461
-
Nurture versus nature: The microenvironment in chronic lymphocytic leukemia
-
Burger JA. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program. 2011;2011:96-103.
-
(2011)
Hematol Am Soc Hematol Educ Program
, vol.2011
, pp. 96-103
-
-
Burger, J.A.1
-
4
-
-
20044372326
-
In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells
-
DOI 10.1172/JCI200523409
-
Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005;115(3):755-764. (Pubitemid 40322252)
-
(2005)
Journal of Clinical Investigation
, vol.115
, Issue.3
, pp. 755-764
-
-
Messmer, B.T.1
Messmer, D.2
Allen, S.L.3
Kolitz, J.E.4
Kudalkar, P.5
Cesar, D.6
Murphy, E.J.7
Koduru, P.8
Ferrarini, M.9
Zupo, S.10
Cutrona, G.11
Damle, R.N.12
Wasil, T.13
Rai, K.R.14
Hellerstein, M.K.15
Chiorazzi, N.16
-
5
-
-
84881266955
-
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia
-
Rossi D, Spina V, Bomben R, et al. Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. Blood. 2013;121(24):4902-4905.
-
(2013)
Blood
, vol.121
, Issue.24
, pp. 4902-4905
-
-
Rossi, D.1
Spina, V.2
Bomben, R.3
-
6
-
-
55949116983
-
Microenvironmental influences in chronic lymphocytic leukaemia: The role of antigen stimulation
-
Ghia P, Chiorazzi N, Stamatopoulos K. Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. J Intern Med. 2008;264(6):549-562.
-
(2008)
J Intern Med
, vol.264
, Issue.6
, pp. 549-562
-
-
Ghia, P.1
Chiorazzi, N.2
Stamatopoulos, K.3
-
7
-
-
84875802229
-
Biology of chronic lymphocytic leukemia in different microenvironments: Clinical and therapeutic implications
-
Herishanu Y, Katz BZ, Lipsky A, Wiestner A. Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol Oncol Clin North Am. 2013;27(2):173-206.
-
(2013)
Hematol Oncol Clin North Am
, vol.27
, Issue.2
, pp. 173-206
-
-
Herishanu, Y.1
Katz, B.Z.2
Lipsky, A.3
Wiestner, A.4
-
8
-
-
80054853285
-
B-cell receptor signaling in chronic lymphocytic leukemia
-
Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2011;118(16): 4313-4320.
-
(2011)
Blood
, vol.118
, Issue.16
, pp. 4313-4320
-
-
Stevenson, F.K.1
Krysov, S.2
Davies, A.J.3
Steele, A.J.4
Packham, G.5
-
9
-
-
55749091407
-
Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA
-
Chu CC, Catera R, Hatzi K, et al. Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood. 2008;112(13): 5122-5129.
-
(2008)
Blood
, vol.112
, Issue.13
, pp. 5122-5129
-
-
Chu, C.C.1
Catera, R.2
Hatzi, K.3
-
10
-
-
43549093570
-
A new perspective: Molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies
-
Lanemo Myhrinder A, Hellqvist E, Sidorova E, et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood. 2008;111(7):3838-3848.
-
(2008)
Blood
, vol.111
, Issue.7
, pp. 3838-3848
-
-
Lanemo Myhrinder, A.1
Hellqvist, E.2
Sidorova, E.3
-
11
-
-
84858019141
-
Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen
-
Steininger C, Widhopf GF II, Ghia EM, et al. Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen. Blood. 2012;119(10):2293-2301.
-
(2012)
Blood
, vol.119
, Issue.10
, pp. 2293-2301
-
-
Steininger, C.1
Widhopf II, G.F.2
Ghia, E.M.3
-
12
-
-
84874542878
-
A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi
-
Hoogeboom R, van Kessel KP, Hochstenbach F, et al. A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. J Exp Med. 2013;210(1):59-70.
-
(2013)
J Exp Med
, vol.210
, Issue.1
, pp. 59-70
-
-
Hoogeboom, R.1
Van Kessel, K.P.2
Hochstenbach, F.3
-
13
-
-
79955513805
-
Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia
-
Amrein PC, Attar EC, Takvorian T, et al. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2011; 17(9):2977-2986.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.9
, pp. 2977-2986
-
-
Amrein, P.C.1
Attar, E.C.2
Takvorian, T.3
-
14
-
-
77951002653
-
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
-
Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115(13):2578-2585.
-
(2010)
Blood
, vol.115
, Issue.13
, pp. 2578-2585
-
-
Friedberg, J.W.1
Sharman, J.2
Sweetenham, J.3
-
15
-
-
80053079880
-
Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia
-
abstr 6631
-
Coutre SE, Byrd JC, Furman RR, et al. Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2011;29(suppl): abstr 6631.
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
-
-
Coutre, S.E.1
Byrd, J.C.2
Furman, R.R.3
-
16
-
-
84896692766
-
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia
-
Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014; 370(11):997-1007.
-
(2014)
N Engl J Med
, vol.370
, Issue.11
, pp. 997-1007
-
-
Furman, R.R.1
Sharman, J.P.2
Coutre, S.E.3
-
17
-
-
84871806385
-
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/ refractory B-cell malignancies
-
Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/ refractory B-cell malignancies. J Clin Oncol. 2013; 31(1):88-94.
-
(2013)
J Clin Oncol
, vol.31
, Issue.1
, pp. 88-94
-
-
Advani, R.H.1
Buggy, J.J.2
Sharman, J.P.3
-
18
-
-
84886433032
-
Phase 1 study of single agent CC-292, a highly selective Bruton's tyrosine kinase (BTK) inhibitor, in relapsed/refractory chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma (B-NHL)
-
Brown JR, Harb W, Sharman J, et al. Phase 1 study of single agent CC-292, a highly selective Bruton's tyrosine kinase (BTK) inhibitor, in relapsed/refractory chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma (B-NHL). Haematologica. 2013;98(s1):S520.
-
(2013)
Haematologica
, vol.98
, Issue.S1
-
-
Brown, J.R.1
Harb, W.2
Sharman, J.3
-
19
-
-
84879748062
-
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
-
Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
-
(2013)
N Engl J Med
, vol.369
, Issue.1
, pp. 32-42
-
-
Byrd, J.C.1
Furman, R.R.2
Coutre, S.E.3
-
20
-
-
84891373281
-
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: An open-label, multicentre, phase 1b/2 trial
-
O'Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15(1):48-58.
-
(2014)
Lancet Oncol
, vol.15
, Issue.1
, pp. 48-58
-
-
O'Brien, S.1
Furman, R.R.2
Coutre, S.E.3
-
21
-
-
84860433198
-
Bruton tyrosine kinase (BTK) and its role in B-cell malignancy
-
Buggy JJ, Elias L. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol. 2012;31(2):119-132.
-
(2012)
Int Rev Immunol
, vol.31
, Issue.2
, pp. 119-132
-
-
Buggy, J.J.1
Elias, L.2
-
22
-
-
79959404661
-
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
-
Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287- 6296.
-
(2011)
Blood
, vol.117
, Issue.23
, pp. 6287-6296
-
-
Herman, S.E.1
Gordon, A.L.2
Hertlein, E.3
-
23
-
-
84897901864
-
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)
-
Woyach JA, Bojnik E, Ruppert AS, et al. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood. 2014; 123(8):1207-1213.
-
(2014)
Blood
, vol.123
, Issue.8
, pp. 1207-1213
-
-
Woyach, J.A.1
Bojnik, E.2
Ruppert, A.S.3
-
24
-
-
84883184095
-
Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia
-
Kil LP, de Bruijn MJ, van Hulst JA, Langerak AW, Yuvaraj S, Hendriks RW. Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia. Am J Blood Res. 2013;3(1):71-83.
-
(2013)
Am J Blood Res
, vol.3
, Issue.1
, pp. 71-83
-
-
Kil, L.P.1
De Bruijn, M.J.2
Van Hulst, J.A.3
Langerak, A.W.4
Yuvaraj, S.5
Hendriks, R.W.6
-
25
-
-
38049084406
-
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase
-
Pan Z, Scheerens H, Li SJ, et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem. 2007;2(1): 58-61.
-
(2007)
ChemMedChem
, vol.2
, Issue.1
, pp. 58-61
-
-
Pan, Z.1
Scheerens, H.2
Li, S.J.3
-
26
-
-
77955625479
-
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
-
Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107(29):13075-13080.
-
(2010)
Proc Natl Acad Sci USA
, vol.107
, Issue.29
, pp. 13075-13080
-
-
Honigberg, L.A.1
Smith, A.M.2
Sirisawad, M.3
-
27
-
-
84881225049
-
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
-
Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013; 369(6):507-516.
-
(2013)
N Engl J Med
, vol.369
, Issue.6
, pp. 507-516
-
-
Wang, M.L.1
Rule, S.2
Martin, P.3
-
28
-
-
84871765731
-
Targeting B-Cell receptor signaling for anticancer therapy: The Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies
-
Wiestner A. Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol. 2013;31(1):128-130.
-
(2013)
J Clin Oncol
, vol.31
, Issue.1
, pp. 128-130
-
-
Wiestner, A.1
-
29
-
-
84863011553
-
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
-
Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012; 119(5):1182-1189.
-
(2012)
Blood
, vol.119
, Issue.5
, pp. 1182-1189
-
-
Ponader, S.1
Chen, S.S.2
Buggy, J.J.3
-
30
-
-
84890438137
-
Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy
-
Herman SE, Sun X, McAuley EM, et al. Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy. Leukemia. 2013;27(12):2311-2321.
-
(2013)
Leukemia
, vol.27
, Issue.12
, pp. 2311-2321
-
-
Herman, S.E.1
Sun, X.2
McAuley, E.M.3
-
31
-
-
84895785316
-
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity
-
Cheng S, Ma J, Guo A, et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia. 2014;28(3):649-657.
-
(2014)
Leukemia
, vol.28
, Issue.3
, pp. 649-657
-
-
Cheng, S.1
Ma, J.2
Guo, A.3
-
32
-
-
84881475893
-
Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia
-
Herman SE, Barr PM, McAuley EM, Liu D, Wiestner A, Friedberg JW. Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia. Leukemia. 2013;27(8):1769-1773.
-
(2013)
Leukemia
, vol.27
, Issue.8
, pp. 1769-1773
-
-
Herman, S.E.1
Barr, P.M.2
McAuley, E.M.3
Liu, D.4
Wiestner, A.5
Friedberg, J.W.6
-
33
-
-
84896464977
-
Single Agent Ibrutinib (PCI-32765) Achieves Equally Good and Durable Responses In Chronic Lymphocytic Leukemia (CLL) Patients With and Without Deletion 17p
-
Farooqui M, Aue G, Valdez J, et al. Single Agent Ibrutinib (PCI-32765) Achieves Equally Good and Durable Responses In Chronic Lymphocytic Leukemia (CLL) Patients With and Without Deletion 17p. Blood. 2013; 122(21):673.
-
(2013)
Blood
, vol.122
, Issue.21
, pp. 673
-
-
Farooqui, M.1
Aue, G.2
Valdez, J.3
-
34
-
-
77957664665
-
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, openlabel, phase 3 trial
-
International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group
-
Hallek M, Fischer K, Fingerle-Rowson G, et al International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, openlabel, phase 3 trial. Lancet. 2010;376(9747): 1164-1174.
-
(2010)
Lancet
, vol.376
, Issue.9747
, pp. 1164-1174
-
-
Hallek, M.1
Fischer, K.2
Fingerle-Rowson, G.3
-
35
-
-
84866152172
-
Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling
-
Dühren-von Minden M, Übelhart R, Schneider D, et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature. 2012;489(7415):309-312.
-
(2012)
Nature
, vol.489
, Issue.7415
, pp. 309-312
-
-
Dühren-von Minden, M.1
Übelhart, R.2
Schneider, D.3
-
36
-
-
84884523966
-
Ibrutinib in relapsed chronic lymphocytic leukemia
-
Byrd JC, O'Brien S, James DF. Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(13):1278-1279.
-
(2013)
N Engl J Med
, vol.369
, Issue.13
, pp. 1278-1279
-
-
Byrd, J.C.1
O'Brien, S.2
James, D.F.3
-
37
-
-
78751530756
-
Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation
-
Pérez-Galán P, Mora-Jensen H, Weniger MA, et al. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood. 2011;117(2):542-552.
-
(2011)
Blood
, vol.117
, Issue.2
, pp. 542-552
-
-
Pérez-Galán, P.1
Mora-Jensen, H.2
Weniger, M.A.3
-
38
-
-
79960982758
-
Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma
-
Weniger MA, Rizzatti EG, Pérez-Galán P, et al. Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. Clin Cancer Res. 2011;17(15):5101-5112.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.15
, pp. 5101-5112
-
-
Weniger, M.A.1
Rizzatti, E.G.2
Pérez-Galán, P.3
-
39
-
-
73849145729
-
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
-
Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277): 88-92.
-
(2010)
Nature
, vol.463
, Issue.7277
, pp. 88-92
-
-
Davis, R.E.1
Ngo, V.N.2
Lenz, G.3
-
40
-
-
19944428834
-
Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling
-
Lam LT, Davis RE, Pierce J, et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res. 2005;11(1):28-40. (Pubitemid 40075775)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.1
, pp. 28-40
-
-
Lam, L.T.1
Davis, R.E.2
Pierce, J.3
Hepperle, M.4
Xu, Y.5
Hottelet, M.6
Nong, Y.7
Wen, D.8
Adams, J.9
Dang, L.10
Staudt, L.M.11
-
41
-
-
33846258010
-
BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway
-
DOI 10.1182/blood-2006-06-027755
-
Endo T, Nishio M, Enzler T, et al. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood. 2007;109(2): 703-710. (Pubitemid 46105972)
-
(2007)
Blood
, vol.109
, Issue.2
, pp. 703-710
-
-
Endo, T.1
Nishio, M.2
Enzler, T.3
Cottam, H.B.4
Fukuda, T.5
James, D.F.6
Karin, M.7
Kipps, T.J.8
-
42
-
-
70350771183
-
The role of toll-like receptors in chronic B-cell malignancies
-
Muzio M, Bertilaccio MT, Simonetti G, Frenquelli M, Caligaris-Cappio F. The role of toll-like receptors in chronic B-cell malignancies. Leuk Lymphoma. 2009;50(10):1573-1580.
-
(2009)
Leuk Lymphoma
, vol.50
, Issue.10
, pp. 1573-1580
-
-
Muzio, M.1
Bertilaccio, M.T.2
Simonetti, G.3
Frenquelli, M.4
Caligaris-Cappio, F.5
-
43
-
-
79953282681
-
Syk mediates BCR- and CD40-signaling integration during B cell activation
-
Ying H, Li Z, Yang L, Zhang J. Syk mediates BCR- and CD40-signaling integration during B cell activation. Immunobiology. 2011;216(5):566-570.
-
(2011)
Immunobiology
, vol.216
, Issue.5
, pp. 566-570
-
-
Ying, H.1
Li, Z.2
Yang, L.3
Zhang, J.4
-
44
-
-
70249086961
-
Signalling crosstalk in B cells: Managing worth and need
-
Cancro MP. Signalling crosstalk in B cells: managing worth and need. Nat Rev Immunol. 2009;9(9):657-661.
-
(2009)
Nat Rev Immunol
, vol.9
, Issue.9
, pp. 657-661
-
-
Cancro, M.P.1
-
45
-
-
84870734255
-
Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia
-
Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood. 2012;120(24):4684-4691.
-
(2012)
Blood
, vol.120
, Issue.24
, pp. 4684-4691
-
-
Wiestner, A.1
-
46
-
-
84897069190
-
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy
-
Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123(12): 1810-1817.
-
(2014)
Blood
, vol.123
, Issue.12
, pp. 1810-1817
-
-
Woyach, J.A.1
Smucker, K.2
Smith, L.L.3
-
47
-
-
84888216911
-
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
-
Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15): 2539-2549.
-
(2013)
Blood
, vol.122
, Issue.15
, pp. 2539-2549
-
-
Dubovsky, J.A.1
Beckwith, K.A.2
Natarajan, G.3
-
48
-
-
69149095639
-
The role of Tec family kinases in mononuclear phagocytes
-
Koprulu AD, Ellmeier W. The role of Tec family kinases in mononuclear phagocytes. Crit Rev Immunol. 2009;29(4):317-333.
-
(2009)
Crit Rev Immunol
, vol.29
, Issue.4
, pp. 317-333
-
-
Koprulu, A.D.1
Ellmeier, W.2
-
49
-
-
84891373612
-
Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL)
-
Chang BY, Furman RR, Zapatka M, et al. Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL). J Clin Oncol. 2013; 31(suppl 1):7014.
-
(2013)
J Clin Oncol
, vol.31
, Issue.SUPPL. 1
, pp. 7014
-
-
Chang, B.Y.1
Furman, R.R.2
Zapatka, M.3
-
50
-
-
84922322355
-
Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: Correlative analyses from a phase II study
-
published online ahead of print April 4, doi: 10.1038/leu.2014.122
-
Herman SEM, Carsten NU, Farooqui M, et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study [published online ahead of print April 4, 2014]. Leukemia. doi: 10.1038/leu.2014.122.
-
(2014)
Leukemia
-
-
Herman, S.E.M.1
Carsten, N.U.2
Farooqui, M.3
|